Hudson Acquisition I Corp. (NASDAQ:HUDA) announced that it has signed a non-binding letter of intent (LOI) to combine with a pre-clinical-stage biotechnology company.
The SPAC did not provide many details on the unnamed target, but disclosed that the biotech company is focused on developing intranasal preventives for major disease-causing respiratory viruses.
As a condition to the target company, Hudson’s board and executive officers will appoint new personnel to replace them and resign simultaneously.
Since Hudson has a completion deadline of July 28, and the ability to extend up to an extra 6 months, this announcement does not appear to be a pure teaser ahead of an extension vote. Hudson priced its $60 million IPO in October 2022 and initially set out to identify a well-established target focused on fintech, consumer, medical, or advanced mobility technology. The SPAC is led by Chairman and CEO Jiang Hui, CFO Hon Man Yu, and Senior Advisor Pengfei Xie.
But, since Hudson’s deal is at the non-binding LOI stage, SPACInsider will not consider this deal as fully “announced”. As such, it will remain in the “Searching” category until a definitive agreement is signed.
ChampionsGate Acquisition Corporation (NASDAQ:CHPGU) has filed for a $200 million SPAC and is underwriter Clear Street’s fifth SPAC to file so far this year. This puts Clear Street above recent SPAC mainstays like EF Hutton, Maxim Group and Alliance Global partners and it appears to have carved out a portion of the market for itself,...
At the SPAC of Dawn Tuesday brings a big day of US retail sales readings, which generally get outsized attention in the thick of the holiday season. A pair of US retail sales indicators are set to report at 8:30 am ET, while industrial production figures and capacity utilization are set for a 9:15 am...
Jackson Acquisition Company II (NYSE:JACS.U) announced the pricing of its $200 million IPO and its units are expected to begin trading on the NYSE under the symbol “JACS.U”, Tuesday, December 10 2024. The new SPAC intends to search for a healthcare target that can benefit from its team’s relationships within the healthcare services space nationally....
SPAC deal flow has hit a slump in the second half of 2024 as the SPAC ecosystem transitions from one generation of SPACs to another. This year started with 128 SPACs still searching for a target and 102 SPACs are still in that state today. So, one might expect a more vigorous pace of announced...
At the SPAC of Dawn The second week of December kicks off with plenty of business on the schedule. Eight SPACs are holding votes of some kind while both Swiftmerge (NASDAQ:IVCP) and Mars (NASDAQ:MARX) ask their shareholders for approval of their deals. Swiftmerge has been working to take natural gas producer AleAnna public since June...